The underlying reason for this dip is the biotech’s inability to shake off the political turmoil surrounding specialty-drug prices last year. And that’s not exactly surprising, given that Biogen’s flagship multiple sclerosis drug Tecfidera relied heavily on price increases to drive sales growth in the U.S. in 2016.